Park Ha Biological Technology Co., Ltd. Ordinary Shares
BYAH · NASDAQ
Company research
Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) is a China-based investment holding company founded in 2016 and headquartered in Wuxi, Jiangsu Province, that develops and sells private-label skincare products under its proprietary "Park Ha" brand, targeting consumers with problematic skin. The company operates through two segments — Product Sales and Franchise Service — offering nearly 128 skincare products across 14 series, including categories such as basic skin physical protection, exfoliation, sebum film repair, surface microecological balance, and anti-aging, with star products like the Little Blue Injection Serum. It distributes its products through directly operated retail stores and a network of franchisees across the People's Republic of China, while also providing a complimentary "light beauty experience" after-sales beauty service in both directly operated and franchise locations. The company has additionally formed strategic partnerships to build AI-powered skincare and beauty ecosystems, reflecting its commitment to innovation in the Chinese personal care market.
Research reports
Danelfin’s AI-powered report assigns BYAH an AI Score of 1/10 (Strong Sell), highlighting a significantly below-average probability of beating the market over the next 3 months driven by weak fundamentals, negative sentiment, and extreme volatility. It notes a one-year analyst price target around 1.51 USD and stresses that lack of institutional ownership, poor risk-adjusted returns, and high volatility make the risk/reward profile very unattractive.
Timothy Sykes News · June 12, 2026BYAH Stock Whipsaws After Parabolic Spike, Drawing Momentum …Timothy Sykes News analyzes BYAH as a tiny, highly volatile micro-cap that recently spiked from near 1 USD to above 6 USD before collapsing, using this move to illustrate liquidity, trading setups, and key chart levels. The piece reviews fundamentals such as modest revenue, decent cash and low debt but extremely negative returns on capital and retained earnings, concluding that traders should treat BYAH as a short-term trading vehicle with strict risk management rather than a long-term investment.